Aging Clinical Trial
— LILACOfficial title:
Cardiometabolic Consequences of the Loss of Ovarian Function
The menopause transition is associated with a decrease in artery health and an increased risk for weight gain in storing fat in the stomach area which may increase the risk for heart disease. The purpose of this research is to study how the decrease in estrogen at menopause changes artery health and fat gain, and risk of disease in women as they age. The first aim in this study will determine whether short term and long term low estrogen levels in premenopausal women decreases artery function and whether this is related to an increase in fat in the stomach area. The second aim will determine whether the changes in artery health and body fat are related to changes in a pathway that breaks down an important amino acid called tryptophan. This pathway is thought to play a role in regulating the aging process. Therefore, the investigators will determine whether the decrease in artery health and the increase in body fat in the stomach region with low estrogen is related to changes in this pathway in the blood, in vascular cells and fat tissue. Because estrogen levels fluctuate in premenopausal women, the investigators will use an approach (intervention) that controls estrogen levels to address these aims. The investigators will use a medication that is typically used to treat endometriosis or uterine fibroids to lower estrogen levels and an estrogen patch to increase estrogen in some women. Some women will receive a patch that has no estrogen (called a placebo patch). The intervention period will be 20 weeks. The study will provide us with new knowledge on how low estrogen with menopause affects artery health and fat gain estrogen.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | August 31, 2028 |
Est. primary completion date | May 31, 2028 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 20 Years to 45 Years |
Eligibility | Inclusion Criteria: - Age criteria of 20-45 years: the investigators are determining the effects of ovarian suppression on adiposity and vascular in premenopausal women; - Premenopausal defined as normal menstrual cycle function defined as no more than 1 missed cycle in the previous year: irregular menstrual or missed menstrual cycles could indicate that women are anovulatory and/or perimenopause; - Not pregnant or planning to become pregnant; - Not lactating in the last 3 months; - Serum FSH <10 IU/L measured during days 1-10 of the menstrual cycle: to ensure the woman is premenopausal and not perimenopausal; - Not on hormonal contraception in the last 3 months; - Sedentary or recreationally active (<2 days/wk vigorous exercise); - No use of medications that might influence vascular function (i.e., antihypertensives, lipid lowering medications, blood thinners); - No use of antioxidant supplements or chronic NSAIDs or be willing to go off them for 4 weeks prior to enrollment in the study; Exclusion Criteria: - Diabetic or fasted glucose >126 mg/dL; - Body mass index (BMI) >35 kg/m2; - Weight change >5 kg in the last 3 months; - Use of glucocorticoids (inhaled, oral, topical) or drugs that affect glucocorticoid metabolism (e.g., ketoconazole) in the last 3 months; - Excess alcohol consumption, defined as >14 drinks per week by self-report; - Known hypersensitivity to study medications; - Depressive symptoms, defined as a CES-D score >16; - Resting blood pressure >150/90 mmHg; - Preexisting or active cardiac, renal, or hepatic disease: past or current history of these diseases or conditions; - Active or chronic infection: inflammation associated with active or chronic infections impair vascular function; - Thyroid dysfunction, defined as an ultrasensitive TSH <0.5 or >5.0 mU/L; volunteers with abnormal TSH values will be reconsidered for participation in the study after follow-up evaluation by the PCP with initiation or adjustment of thyroid hormone replacement; - Smoking or Tobacco use within the previous 12 months; - Severe low bone mass or osteoporosis, defined as a hip or lumbar spine T-score <-2.0: safety reasons, women who are randomized to the ovarian suppression plus placebo group could see a decrease in bone mineral density due to the suppression of estrogen; - History of venous thromboembolic event (VTE): safety reasons, estradiol therapy can increase the risk of VTE; - History of breast cancer or other estrogen-dependent neoplasm: estradiol therapy is contraindicated; |
Country | Name | City | State |
---|---|---|---|
United States | University of Colorado Anschutz Medical Campus | Aurora | Colorado |
Lead Sponsor | Collaborator |
---|---|
University of Colorado, Denver | National Institute on Aging (NIA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Subcutaneous fat area | Participants will undergo a CT scan of the abdomen for the assessment of VFA and subcutaneous fat area (SFA). Axial CT images will be obtained through the center of the L2-L3 inter-vertebral disc space at 120 kVp, 200-300 maS, and 10mm slice thickness. Digital images will be analyzed in a blinded manner by the University of Colorado Research Imaging Center (CU-RIC) using Interactive Data language software (ITT Visualization Solutions, Boulder, CO). | Baseline and at 20 weeks | |
Other | Tryptophan-Kynurenine metabolites | Mechanistic outcome. Profiling of TRP-KYN metabolism in plasma, adipose tissue, adipocytes, and HAECs (human aortic endothelial cells) will be performed using a targeted mass spectrometry-based high throughput metabolomics platform at the CU-AMC Metabolomics Core (see Dr. D'Alessandro - LOS).114-116 Metabolites will be extracted using 5:3:2 methanol:acetonitrile:water according to established protocols.117 Extracts will be clarified by centrifugation, dried, resuspended in 0.1% formic acid, randomized, and data acquired on a Vanquish UHPLC coupled to a Q Exactive mass spectrometer (Thermo) as previously described.118 TRP-KYN pathway features will be annotated and peaks integrated using Maven (Princeton Univ) in conjunction with the KEGG database and an established in-house compound library. The Core assists with data analysis and interpretation. | Baseline and at 2 and 20 weeks | |
Other | Body composition - mass | DXA (dual-energy X-ray absorptiometry) measurements of total and regional fat mass and fat-free mass in kilograms for screening | Baseline and at 20 weeks | |
Other | Body composition - bone | DXA (dual-energy X-ray absorptiometry) measurements of bone density for screening | Baseline and at 20 weeks | |
Other | Oxidized LDL | Oxidative stress biomarker; measured using ELISA plate assays | Baseline and at 2 and 20 weeks | |
Other | Total antioxidant status | Antioxidant marker that reflects the overall antioxidant capacity of the human plasma, measured using Randox Laboratories enzymatic kit | Baseline and at 2 and 20 weeks | |
Other | Pro-inflammatory cytokines | Cytokine Multiplex Assays in blood | Baseline and at 2 and 20 weeks | |
Other | Blood lipids and lipoproteins | Descriptive variable; total-cholesterol (C), low-density lipoprotein-C, triglycerides, and high-density lipoprotein-C, measured in mg/dL, will be determined using enzymatic/colorimetric methods | Baseline and at 2 and 20 weeks | |
Other | Blood glucose | Descriptive variable; will be measured by enzymatic UV testing | Baseline and at 2 and 20 weeks | |
Other | Insulin | Descriptive variable; will be measured by radioimmunoassay | Baseline and at 2 and 20 weeks | |
Other | Adipokines | Adiponectin and leptin will be measured by radioimmunoassay | Baseline and at 2 and 20 weeks | |
Other | Physical activity levels | Physical activity assessed for 7 days at each time point using ActivPal | Baseline and at 2 and 20 weeks | |
Other | Endothelial cell protein measures | Mechanistic outcome. Endothelial cells will be collected from an antecubital vein, using 2 sterile J-wires advanced and retracted through an intravenous catheter. Cells will be processed and frozen on slides for the assessment of various proteins using microscopy including enzymes in the TRP-KYN pathway (IDO, KAT1, KMO), NADPH oxidase, NFkB, eNOS, and other proteins. | Baseline and at 2 and 20 weeks | |
Other | Ex vivo serum exposure studies | Mechanistic exploratory outcome. Human aortic endothelial cells from 3 different female donors (Lonza) will be cultured under standard culture conditions (37°C, 20% O2, 5% CO2, humidified) with varying experimental conditions as described below. After culturing, cells will be stained with the fluorescent probe DAF-FM diacetate (to detect NO) and imaged before and 5 min after addition of 200 | Baseline and at 2 and 20 weeks | |
Other | Cerebrovascular function | Transcranial Doppler of the middle cerebral artery at rest and response to hypercapnia | Baseline and at 2 and 20 weeks | |
Other | Arterial Stiffness | Determined using pulse wave velocity, which measures the time delay between when a pulse is detected in the carotid artery and a pulse is detected in the femoral artery | Baseline and at 2 and 20 weeks | |
Other | Carotid artery stiffness | Ultrasound of the carotid artery | Baseline and at 2 and 20 weeks | |
Other | Blood pressure | Seated systolic and diastolic blood pressure | Baseline and at 2 and 20 weeks | |
Other | Self reported sleep quality | Pittsburgh sleep quality index (questionnaire) with a range of total score between 0 to 21 with the higher total score indicating worse sleep quality | Baseline and at 2 and 20 weeks | |
Other | Cognitive function | NIH Toolbox cognitive test battery | Baseline and at 2 and 20 weeks | |
Primary | Brachial artery flow mediated dilation (FMD) | Ultrasound measurements of brachial artery FMD will be performed in the morning under fasted conditions, and analyzed (Vascular Analysis Tools 5.5.1) according to guidelines. Baseline FMD will be assessed during early follicular phase of menstrual cycle. Blood pressure will be measured prior to the FMD. To confirm endothelial-specific effects of the intervention, the investigators will also measure endothelium-independent dilation as brachial artery dilation to sublingual nitroglycerine (0.4 mg). All ultrasound images will be coded by number and blinded to group assignment. | Baseline and at 2 and 20 weeks | |
Secondary | Visceral fat area (VFA) | Participants will undergo a CT scan of the abdomen for the assessment of VFA and subcutaneous fat area (SFA). Axial CT images will be obtained through the center of the L2-L3 inter-vertebral disc space at 120 kVp (kilovoltage peak), 200-300 maS, and 10mm slice thickness. Digital images will be analyzed in a blinded manner by the University of Colorado Research Imaging Center (CU-RIC) using Interactive Data language software (ITT Visualization Solutions, Boulder, CO). | Baseline and at 20 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Completed |
NCT05293730 -
Trial of the Impact of the Electronic Frailty Integrated With Social Needs
|
N/A | |
Recruiting |
NCT03932162 -
Gene Expression Changes In Young and Geriatric Skin
|
Early Phase 1 | |
Completed |
NCT04064528 -
Effects of Age on Amino Acid Delivery to Tendon
|
N/A | |
Completed |
NCT03366129 -
Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
|
||
Completed |
NCT06029920 -
Influence of Overground Walking on Biomarkers, Cognitive Function, and Quality of Life in Elderly With Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT05543980 -
Leg Heat Therapy in Elderly Individuals
|
Phase 2 | |
Recruiting |
NCT05566938 -
Study to Design a Precision Nutrition Strategy at a Group Level in the Elderly
|
N/A | |
Completed |
NCT04894929 -
Comprehensive Geriatric Assessment in the Monitoring of Functional Improvement
|
N/A | |
Not yet recruiting |
NCT06071130 -
Emotion, Aging, and Decision Making
|
N/A | |
Enrolling by invitation |
NCT04641663 -
Multi-target Dietary Supplement Tolerability in an Aging Population (MTDSST)
|
N/A | |
Completed |
NCT04088006 -
The Evaluation of Efficacy and Safety of Hyaluronic Acid Injection on Skin Moisturization and Elasticity
|
N/A | |
Completed |
NCT03695081 -
Patient Pathway Pharmacist - Optimal Drug-related Care
|
N/A | |
Recruiting |
NCT05424263 -
Acetate and Age-associated Arterial Dysfunction
|
Phase 2 | |
Completed |
NCT05601713 -
Mitigating Heat-induced Physiological Strain and Discomfort in Older Adults Via Lower Limb Immersion and Neck Cooling
|
N/A | |
Completed |
NCT04551339 -
Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19
|
N/A | |
Recruiting |
NCT04997577 -
Speech Perception and High Cognitive Demand
|
N/A | |
Completed |
NCT05922475 -
Efficacy of Pre-sleep or Post-exercise Protein During 12 Weeks of Resistance Exercise Training
|
N/A | |
Completed |
NCT04015479 -
Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older Adults
|
N/A |